SBA Member, 11.10.2017
Zurich-Schlieren, October 9, 2017. Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company that is developing a new class of drugs, known as DARPin® therapies, today published the Invitation to the Extraordinary General Meeting which will be held on Tuesday, October 31, 2017, 2.00 pm CET (doors open at 1.00 pm), at the registered office of the company, 5th floor, Wagistrasse 14, 8952 Schlieren, Switzerland.
At this Extraordinary General Meeting William (Bill) Burns and Patrick Amstutz will be proposed for election to the Board of Directors.
Link to the Invitation to the Extraordinary General Meeting with the corresponding agenda items.
Link zur Einladung zur ausserordentlichen Generalversammlung mit den zugehörigen Traktanden.
October 26, 2017
Q3 2017 Management Statement
October 31, 2017
Extraordinary General Meeting
November 9, 2017
R&D Day in New York
February 8, 2018
Publication of Full-year Results 2017 (unaudited)
March 16, 2018
Expected Publication of 2017 Annual Report
April 18, 2018
Annual General Meeting
Media Release (PDF)
About the DARPin® Difference
DARPin® therapeutics are a new class of protein therapeutics that open an extra dimension of multi-specificity and multi-functionality. DARPin® candidates are potent, specific, safe and very versatile. They can engage more than five targets at once, offering potential benefits over those provided by conventional monoclonal antibodies or other currently available protein therapeutics.
The DARPin® technology is a fast and cost-effective drug discovery engine, producing drug candidates with ideal properties for development and very high production yields. With their good safety profile, low immunogenicity and long half-life in the bloodstream and the eye, DARPin® therapies have the potential to advance modern medicine and significantly improve the treatment of serious diseases, including cancer and sight-threatening disorders. Molecular Partners is partnering with Allergan to advance clinical programs in ophthalmology, and is advancing a proprietary pipeline of DARPin® drug candidates in oncology. The most advanced global product candidate is abicipar, a molecule currently in phase 3, in partnership with Allergan. Several DARPin® molecules for various ophthalmic indications are also in development. The most advanced systemic DARPin® molecule, MP0250, is in a clinical POC study in multiple myeloma. In addition, Molecular Partners intends to evaluate MP0250 for the treatment of solid tumors in a phase 1b/2 trial in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). MP0274, the company’s second-most advanced DARPin® drug candidate in oncology, is entering into phase 1 development. With its broad anti-HER activity, MP0274 inhibits HER1-, HER2- and HER3-mediated downstream signaling via Her2, leading to induction of apoptosis. Molecular Partners is also advancing a growing preclinical pipeline that features several immuno-oncological development programs. DARPin® is a registered trademark owned by Molecular Partners AG.
About Molecular Partners AG
Molecular Partners AG is a clinical-stage biopharmaceutical company that is developing a new class of therapies known as DARPin® therapies. With a management team that includes many of the company’s founding scientists, Molecular Partners continues to attract talented individuals who share a passion for developing breakthrough medicines for serious diseases. Molecular Partners has compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on ophthalmology and oncology. The company establishes research and development partnerships with leading pharmaceutical companies and is backed by established biotech investors.
For more information regarding Molecular Partners AG, go to: www.molecularpartners.com.
For further details, please contact:
Patrick Amstutz, CEO
Andreas Emmenegger, CFO
Tel: +41 44 755 77 00
Tel: +41 44 755 77 00
Susan A. Noonan
S.A. Noonan Communications, LLC
Tel: +41 43 344 42 42
Tel.: +1 212 966 3650
This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Molecular Partners AG. This publication may contain certain forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. The company disclaims any obligation to update these forward-looking statements, assessments or inten